Cargando…
Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: A multicenter randomized study
BACKGROUND: Generally, oral immunotherapy (OIT) aims for daily administration. Recently, the efficacy of treatment with OIT at a low dose has been reported. However, the optimal dose and the evaluation of dose-dependent OIT outcome have not been described. METHODS: A multicenter, parallel, open-labe...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Allergy Organization
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527748/ https://www.ncbi.nlm.nih.gov/pubmed/33024480 http://dx.doi.org/10.1016/j.waojou.2020.100463 |
_version_ | 1783589123034972160 |
---|---|
author | Ogura, Kiyotake Yanagida, Noriyuki Sato, Sakura Imai, Takanori Ito, Komei Kando, Naoyuki Ikeda, Masanori Shibata, Rumiko Murakami, Yoko Fujisawa, Takao Nagao, Mizuho Kawamoto, Norio Kondo, Naomi Urisu, Atsuo Tsuge, Ikuya Kondo, Yasuto Sugai, Kazuko Uchida, Osamu Urashima, Mitsuyoshi Taniguchi, Masami Ebisawa, Motohiro |
author_facet | Ogura, Kiyotake Yanagida, Noriyuki Sato, Sakura Imai, Takanori Ito, Komei Kando, Naoyuki Ikeda, Masanori Shibata, Rumiko Murakami, Yoko Fujisawa, Takao Nagao, Mizuho Kawamoto, Norio Kondo, Naomi Urisu, Atsuo Tsuge, Ikuya Kondo, Yasuto Sugai, Kazuko Uchida, Osamu Urashima, Mitsuyoshi Taniguchi, Masami Ebisawa, Motohiro |
author_sort | Ogura, Kiyotake |
collection | PubMed |
description | BACKGROUND: Generally, oral immunotherapy (OIT) aims for daily administration. Recently, the efficacy of treatment with OIT at a low dose has been reported. However, the optimal dose and the evaluation of dose-dependent OIT outcome have not been described. METHODS: A multicenter, parallel, open-labeled, prospective, non-placebo controlled, randomized study enrolled 101 Japanese patients for treatment with OIT. We hypothesized that target dose OIT would induce short-term unresponsiveness (StU) earlier than reduced dose OIT. StU was defined as no response to 6200 mg whole egg, 3400 mg milk, and 2600 mg wheat protein, as evaluated by oral food challenge after 2-week ingestion cessation. To compare the two doses of OIT efficacy, the maximum ingestion doses during the maintenance phase of OIT were divided into 100%-dose or 25%-dose groups against their target StU dose, respectively. A total of 51 patients were assigned to the 100%-dose group [hen's egg (HE) = 26, cow's milk (CM) = 13, wheat = 12] and 50 to the 25%-dose group (HE = 25, CM = 13, wheat = 12). Primary outcome was established by comparing StU at 1 year. Secondary outcome was StU at 2 years and established by comparing allergic symptoms and immunological changes. RESULTS: The year 1 StU rates (%) for the 100%- and 25%-dose groups were 26.9 vs. 20.0 (HE), 7.7 vs. 15.4 (CM), and 50.0 vs. 16.7 (wheat), respectively. The year 2 StU rates were 30.8 vs. 36.0 (HE), 7.7 vs. 23.1 (CM), and 58.3 vs. 58.3 (wheat), respectively. There were no statistically significant differences in StU between years 1 and 2. The total allergic symptom rate in the 25%-dose group was lower than that in the 100%-dose group for egg, milk, and wheat. Antigen-specific IgE levels for egg-white, milk, and wheat decreased at 12 months. CONCLUSIONS: Reduced maintenance dose of egg OIT showed similar therapeutic efficacy to the target dose. However, we were not able to clearly demonstrate the efficacy, particularly for milk and wheat. Reducing the maintenance dose for eggs, milk, and wheat may effectively lower the symptoms associated with their consumption compared to the target OIT dose. Furthermore, aggressive reduction of the maintenance dose might be important for milk and wheat, compared to the 25%-dose OIT. TRIAL REGISTRATION: UMIN000009373, Multicenter Oral Immunotherapy for Hen's Egg, Cow's Milk, and Wheat-Allergic Children at Outpatient Clinic. |
format | Online Article Text |
id | pubmed-7527748 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | World Allergy Organization |
record_format | MEDLINE/PubMed |
spelling | pubmed-75277482020-10-05 Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: A multicenter randomized study Ogura, Kiyotake Yanagida, Noriyuki Sato, Sakura Imai, Takanori Ito, Komei Kando, Naoyuki Ikeda, Masanori Shibata, Rumiko Murakami, Yoko Fujisawa, Takao Nagao, Mizuho Kawamoto, Norio Kondo, Naomi Urisu, Atsuo Tsuge, Ikuya Kondo, Yasuto Sugai, Kazuko Uchida, Osamu Urashima, Mitsuyoshi Taniguchi, Masami Ebisawa, Motohiro World Allergy Organ J Article BACKGROUND: Generally, oral immunotherapy (OIT) aims for daily administration. Recently, the efficacy of treatment with OIT at a low dose has been reported. However, the optimal dose and the evaluation of dose-dependent OIT outcome have not been described. METHODS: A multicenter, parallel, open-labeled, prospective, non-placebo controlled, randomized study enrolled 101 Japanese patients for treatment with OIT. We hypothesized that target dose OIT would induce short-term unresponsiveness (StU) earlier than reduced dose OIT. StU was defined as no response to 6200 mg whole egg, 3400 mg milk, and 2600 mg wheat protein, as evaluated by oral food challenge after 2-week ingestion cessation. To compare the two doses of OIT efficacy, the maximum ingestion doses during the maintenance phase of OIT were divided into 100%-dose or 25%-dose groups against their target StU dose, respectively. A total of 51 patients were assigned to the 100%-dose group [hen's egg (HE) = 26, cow's milk (CM) = 13, wheat = 12] and 50 to the 25%-dose group (HE = 25, CM = 13, wheat = 12). Primary outcome was established by comparing StU at 1 year. Secondary outcome was StU at 2 years and established by comparing allergic symptoms and immunological changes. RESULTS: The year 1 StU rates (%) for the 100%- and 25%-dose groups were 26.9 vs. 20.0 (HE), 7.7 vs. 15.4 (CM), and 50.0 vs. 16.7 (wheat), respectively. The year 2 StU rates were 30.8 vs. 36.0 (HE), 7.7 vs. 23.1 (CM), and 58.3 vs. 58.3 (wheat), respectively. There were no statistically significant differences in StU between years 1 and 2. The total allergic symptom rate in the 25%-dose group was lower than that in the 100%-dose group for egg, milk, and wheat. Antigen-specific IgE levels for egg-white, milk, and wheat decreased at 12 months. CONCLUSIONS: Reduced maintenance dose of egg OIT showed similar therapeutic efficacy to the target dose. However, we were not able to clearly demonstrate the efficacy, particularly for milk and wheat. Reducing the maintenance dose for eggs, milk, and wheat may effectively lower the symptoms associated with their consumption compared to the target OIT dose. Furthermore, aggressive reduction of the maintenance dose might be important for milk and wheat, compared to the 25%-dose OIT. TRIAL REGISTRATION: UMIN000009373, Multicenter Oral Immunotherapy for Hen's Egg, Cow's Milk, and Wheat-Allergic Children at Outpatient Clinic. World Allergy Organization 2020-09-29 /pmc/articles/PMC7527748/ /pubmed/33024480 http://dx.doi.org/10.1016/j.waojou.2020.100463 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ogura, Kiyotake Yanagida, Noriyuki Sato, Sakura Imai, Takanori Ito, Komei Kando, Naoyuki Ikeda, Masanori Shibata, Rumiko Murakami, Yoko Fujisawa, Takao Nagao, Mizuho Kawamoto, Norio Kondo, Naomi Urisu, Atsuo Tsuge, Ikuya Kondo, Yasuto Sugai, Kazuko Uchida, Osamu Urashima, Mitsuyoshi Taniguchi, Masami Ebisawa, Motohiro Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: A multicenter randomized study |
title | Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: A multicenter randomized study |
title_full | Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: A multicenter randomized study |
title_fullStr | Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: A multicenter randomized study |
title_full_unstemmed | Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: A multicenter randomized study |
title_short | Evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: A multicenter randomized study |
title_sort | evaluation of oral immunotherapy efficacy and safety by maintenance dose dependency: a multicenter randomized study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527748/ https://www.ncbi.nlm.nih.gov/pubmed/33024480 http://dx.doi.org/10.1016/j.waojou.2020.100463 |
work_keys_str_mv | AT ogurakiyotake evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT yanagidanoriyuki evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT satosakura evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT imaitakanori evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT itokomei evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT kandonaoyuki evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT ikedamasanori evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT shibatarumiko evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT murakamiyoko evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT fujisawatakao evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT nagaomizuho evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT kawamotonorio evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT kondonaomi evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT urisuatsuo evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT tsugeikuya evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT kondoyasuto evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT sugaikazuko evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT uchidaosamu evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT urashimamitsuyoshi evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT taniguchimasami evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy AT ebisawamotohiro evaluationoforalimmunotherapyefficacyandsafetybymaintenancedosedependencyamulticenterrandomizedstudy |